Gallic acid emerges as a multitarget agent capable of alleviating depression-pain comorbidity through selective inhibition of P2X7 receptor expression across hippocampal, spinal cord, and dorsal root ganglion tissues (Wen et al., 2022). Here, P2RX7 is linked to depressive symptom measurement.